CCR5 and melanoma: Then, together with Viktor Umansky and his team, this study was further extended to a transgenic model of melanoma showing that indeed the CCR5-CCR5 ligand axis directs the accumulation of PMN-MDSC at the tumor site and that CCR5-Ig also effectively inhibited the development and progression of this disease (117).